WVE-120101 ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 8 | ハンチントン病 | 10 |
8. ハンチントン病
臨床試験数 : 242 / 薬物数 : 205 - (DrugBank : 62) / 標的遺伝子数 : 85 - 標的パスウェイ数 : 159
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2019-003637-42-DE (EUCTR) | 28/07/2020 | 09/06/2020 | A Multicenter, Open-label Extension Study to Evaluate the Safety, Pharmacodynamics, and Clinical Effects of WVE-120101 in Patients with Huntington’s Disease | A Multicenter, Open-label Extension Study to Evaluate the Safety, Pharmacodynamics, and Clinical Effects of WVE-120101 in Patients with Huntington’s Disease | Huntington's Disease MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Product Name: WVE-120101 Product Code: WVE-120101 INN or Proposed INN: WVE-120101 | Wave Life Sciences UK Limited | NULL | Not Recruiting | Female: yes Male: yes | 50 | Phase 2 | France;Canada;Poland;Denmark;Australia;Germany;United Kingdom | ||
| 2 | EUCTR2019-003637-42-FR (EUCTR) | 23/07/2020 | 05/05/2020 | A Multicenter, Open-label Extension Study to Evaluate the Safety, Pharmacodynamics, and Clinical Effects of WVE-120101 in Patients with Huntington’s Disease | A Multicenter, Open-label Extension Study to Evaluate the Safety, Pharmacodynamics, and Clinical Effects of WVE-120101 in Patients with Huntington’s Disease | Huntington's Disease MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Product Name: WVE-120101 Product Code: WVE-120101 INN or Proposed INN: WVE-120101 | Wave Life Sciences UK Limited | NULL | Not Recruiting | Female: yes Male: yes | 50 | Phase 2 | France;Canada;Poland;Denmark;Australia;Germany;United Kingdom | ||
| 3 | EUCTR2019-003637-42-DK (EUCTR) | 06/07/2020 | 02/03/2020 | A Multicenter, Open-label Extension Study to Evaluate the Safety, Pharmacodynamics, and Clinical Effects of WVE-120101 in Patients with Huntington’s Disease | A Multicenter, Open-label Extension Study to Evaluate the Safety, Pharmacodynamics, and Clinical Effects of WVE-120101 in Patients with Huntington’s Disease | Huntington's Disease MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders MedDRA version: 20.1;Level: LLT;Classification code 10012278;Term: Dementia due to Huntington's disease;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Product Name: WVE-120101 Product Code: WVE-120101 INN or Proposed INN: WVE-120101 | Wave Life Sciences UK Limited | NULL | Not Recruiting | Female: yes Male: yes | 50 | Phase 2 | France;Canada;Poland;Australia;Denmark;Germany;United Kingdom | ||
| 4 | NCT04617847 (ClinicalTrials.gov) | April 13, 2020 | 30/10/2020 | Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease | A Multicenter, Open-label Extension Study to Evaluate the Safety, Pharmacodynamics, and Clinical Effects of WVE-120101 in Patients With Huntington's Disease | Huntington Disease | Drug: WVE-120101 | Wave Life Sciences Ltd. | NULL | Terminated | N/A | N/A | All | 27 | Phase 1/Phase 2 | Australia;Canada;Denmark;France;Germany;Poland;United Kingdom |
| 5 | EUCTR2019-003637-42-PL (EUCTR) | 11/04/2020 | 19/02/2020 | A Multicenter, Open-label Extension Study to Evaluate the Safety, Pharmacodynamics, and Clinical Effects of WVE-120101 in Patients with Huntington’s Disease | A Multicenter, Open-label Extension Study to Evaluate the Safety, Pharmacodynamics, and Clinical Effects of WVE-120101 in Patients with Huntington’s Disease | Huntington's Disease MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Product Name: WVE-120101 Product Code: WVE-120101 INN or Proposed INN: WVE-120101 | Wave Life Sciences UK Limited | NULL | Not Recruiting | Female: yes Male: yes | 50 | Phase 2 | France;Canada;Poland;Denmark;Australia;Germany;United Kingdom | ||
| 6 | EUCTR2016-005095-10-DE (EUCTR) | 20/09/2019 | 04/06/2019 | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120101 Administered Intrathecally in Patients with Huntington’s Disease | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120101 Administered Intrathecally in Patients with Huntington’s Disease | Huntington's Disease MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Product Name: WVE-120101 Product Code: WVE-120101 INN or Proposed INN: WVE-120101 | Wave Life Sciences UK Limited | NULL | Not Recruiting | Female: yes Male: yes | 60 | Phase 1;Phase 2 | France;Canada;Poland;Denmark;Australia;Germany;United Kingdom | ||
| 7 | EUCTR2016-005095-10-FR (EUCTR) | 11/07/2019 | 05/03/2019 | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120101 Administered Intrathecally in Patients with Huntington’s Disease | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120101 Administered Intrathecally in Patients with Huntington’s Disease | Huntington's Disease MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Product Name: WVE-120101 Product Code: WVE-120101 INN or Proposed INN: WVE-120101 | Wave Life Science Ltd. | NULL | Not Recruiting | Female: yes Male: yes | 48 | Phase 1;Phase 2 | United States;France;Canada;Poland;Denmark;Australia;Germany;United Kingdom | ||
| 8 | EUCTR2016-005095-10-DK (EUCTR) | 26/02/2019 | 20/12/2018 | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120101 Administered Intrathecally in Patients with Huntington’s Disease | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120101 Administered Intrathecally in Patients with Huntington’s Disease | Huntington's Disease MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Product Name: WVE-120101 Product Code: WVE-120101 INN or Proposed INN: WVE-120101 | Wave Life Sciences UK Limited | NULL | Not Recruiting | Female: yes Male: yes | 60 | Phase 1;Phase 2 | France;Canada;Poland;Australia;Denmark;Germany;United Kingdom | ||
| 9 | EUCTR2016-005095-10-GB (EUCTR) | 02/08/2018 | 17/10/2017 | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120101 Administered Intrathecally in Patients with Huntington’s Disease | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120101 Administered Intrathecally in Patients with Huntington’s Disease | Huntington's Disease MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Product Name: WVE-120101 Product Code: WVE-120101 INN or Proposed INN: WVE-120101 | Wave Life Sciences UK Limited | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 60 | Phase 1;Phase 2 | Canada;United States;Denmark;Poland;United Kingdom;Australia;France;Germany | ||
| 10 | NCT03225833 (ClinicalTrials.gov) | July 17, 2017 | 17/7/2017 | Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120101 Administered Intrathecally in Patients With Huntington's Disease | Huntington's Disease | Drug: WVE-120101;Drug: Placebo | Wave Life Sciences Ltd. | NULL | Terminated | 25 Years | 65 Years | All | 61 | Phase 1/Phase 2 | Australia;Canada;Denmark;France;Germany;Poland;United Kingdom |